Grant: Engage Grants Program
Ryerson University
$25,000.00
Development and testing of in vitro companion assay for novel hypoxia-activated mitochondrial prodrugs****
FY 2018-19
Summary
Cyclica has developed a new technology, termed Differential Drug Discovery (DDD), to design single molecules capable of targeting multiple proteins simultaneously and retain drug like characteristics. The project will design tumour specific pro-drugs to target mitochondrial respiration. To achieve this Cyclica software developers must design constructs to predict chemical structures that will target various proteins in the mitochondria. Our team will develop a companion assay to test the novel chemical structures designed in the software and substantiate the computer aided predictions. We will perform optimization, benchmarking and assays required for Cyclica to proceed to the commercialization of the novel computational drug discovery application of their AI technology.*
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
536832-2018
Name nom
Karshafian, Raffi
Department département
Physics
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
1
Application title
Development and testing of in vitro companion assay for novel hypoxia-activated mitochondrial prodrugs****
Keyword
NSERC
Application summary
Cyclica has developed a new technology, termed Differential Drug Discovery (DDD), to design single molecules capable of targeting multiple proteins simultaneously and retain drug like characteristics. The project will design tumour specific pro-drugs to target mitochondrial respiration. To achieve this Cyclica software developers must design constructs to predict chemical structures that will target various proteins in the mitochondria. Our team will develop a companion assay to test the novel chemical structures designed in the software and substantiate the computer aided predictions. We will perform optimization, benchmarking and assays required for Cyclica to proceed to the commercialization of the novel computational drug discovery application of their AI technology.*